RKV — Rakovina Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$6.34m
- CA$7.48m
Annual income statement for Rakovina Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.025 | 0.197 | 5.53 | 2.82 | 2.48 |
| Operating Profit | -0.025 | -0.197 | -5.53 | -2.82 | -2.48 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.025 | -0.191 | -5.52 | -2.79 | -2.61 |
| Net Income After Taxes | -0.025 | -0.191 | -5.52 | -2.79 | -2.61 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.025 | -0.191 | -5.52 | -2.79 | -2.61 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.025 | -0.191 | -5.52 | -2.79 | -2.61 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.097 | -0.046 | -0.04 | -0.037 |
| Dividends per Share |